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Background: COPD is a major global cause of mortality and morbidity. PINNACLE-4 
evaluated the efficacy and safety of GFF MDI (glycopyrrolate/formoterol fumarate metered dose 
inhaler) in patients from Asia, Europe, and the USA with moderate-to-very severe COPD.
Methods: In this double-blind, placebo-controlled, Phase III study, patients were randomized 
to treatment with GFF MDI 18/9.6 µg, glycopyrrolate (GP) MDI 18 µg, formoterol fumarate 
(FF) MDI 9.6 µg, or placebo MDI (all twice daily) for 24 weeks. Lung function, patient-reported 
outcomes (symptoms and health-related quality of life), and safety were assessed.
Results: Of the 1,756 patients randomized, 1,740 patients were included in the intent-to-treat 
population (mean age 64.2 years, 74.1% male, and 40.2% Asian). GFF MDI significantly 
improved morning predose trough FEV
1
 at Week 24 (primary endpoint) vs placebo MDI, GP MDI, 
and FF MDI (least squares mean differences: 165, 59, and 72 mL, respectively; all P,0.0001). 
GFF MDI also significantly improved other lung function endpoints vs placebo MDI, GP MDI, 
and FF MDI and patient-reported outcomes vs placebo MDI and GP MDI. A larger proportion of 
patients treated with GFF MDI achieved the minimum clinically important difference in Transition 
Dyspnea Index score vs GP MDI and placebo MDI and in St George’s Respiratory Questionnaire 
score vs placebo MDI. Adverse event rates were similar across treatment groups.
Conclusion: These results demonstrated the efficacy of GFF MDI in patients with moderate-
to-very severe COPD. GFF MDI was well tolerated, with a safety profile commensurate with 
long-acting bronchodilators.
Keywords: β
2
-agonist, bronchodilator, COPD, co-suspension delivery technology, muscarinic 
antagonist
Introduction
Bronchodilators are the cornerstone of maintenance therapy for COPD,1 one of the 
leading causes of mortality and morbidity worldwide.2 Combined treatment with a 
long-acting muscarinic antagonist (LAMA) and a long-acting β
2
-agonist (LABA) 
plays an important role in the stepwise management of COPD.3 The Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) recommends combined LAMA/
LABA treatment as a first-line therapy for patients with COPD in GOLD group D; 
and as a step-up treatment for patients in GOLD group C who experience frequent 
exacerbations despite LAMA or LABA monotherapy, and patients in GOLD group B 
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who experience persistent symptoms despite bronchodilator 
monotherapy.1
Glycopyrrolate/formoterol fumarate metered dose inhaler 
(GFF MDI) 18/9.6 µg (Bevespi Aerosphere®; AstraZeneca, 
Wilmington, DE, USA) is a fixed-dose combination (FDC) 
of the LAMA glycopyrrolate (GP) and the LABA formoterol 
fumarate (FF), formulated using innovative co-suspension 
delivery technology. GFF MDI is approved in the USA for 
the long-term maintenance treatment of airflow obstruction 
in patients with COPD4 and, to date, is the first and only 
LAMA/LABA FDC available as an MDI.
The efficacy and safety of GFF MDI compared with 
respective monocomponents have been demonstrated over 
a period of up to 52 weeks in the pivotal Phase III studies 
PINNACLE-1, PINNACLE-2 (24 weeks; NCT01854645 
and NCT01854658), and PINNACLE-3 (28-week safety 
extension study; NCT01970878), in patients from the USA, 
Australia, and New Zealand.5,6 Due to differences in COPD 
prevalence and burden between different countries and 
regions,7–10 as well as potential differences in the observed 
effects of pharmacological therapies,11 it was deemed impor-
tant to evaluate the efficacy and safety of COPD mainte-
nance treatments in other geographical patient populations. 
Here, we present the results of the PINNACLE-4 study 
(ClinicalTrials.gov: NCT02343458), which investigated 
the efficacy and safety of GFF MDI compared to its mono-
components (GP MDI and FF MDI) and placebo MDI in 
a population with moderate-to-very severe COPD, which 
included Asian and European patients.
Methods
study design and treatment
PINNACLE-4 was a randomized, double-blind, parallel-
group, placebo-controlled Phase III study conducted at 
multiple sites across Asia, Europe, and the USA. Patients 
were randomized 7:6:6:3 using an Interactive Web Response 
System (further details in the Supplementary materials) to 
receive treatment with GFF MDI 18/9.6 µg (equivalent to 
glycopyrronium/formoterol fumarate dihydrate 14.4/10 µg), 
GP MDI 18 µg, FF MDI 9.6 µg, or matched placebo MDI (all 
twice daily) for 24 weeks, with randomization stratified by 
reversibility to rescue albuterol sulfate and by COPD disease 
severity. Patients provided written informed consent prior 
to screening, and the study was conducted in accordance 
with Good Clinical Practice, including the Declaration of 
Helsinki and the International Council for Harmonisation. 
The protocol was approved by local institutional review 
boards (Table S1). Patients were required to discontinue 
prohibited COPD medications (including oral β
2
-agonists, 
LABAs, cromoglycate or nedocromil inhalers, leukotriene 
antagonists, ketotifen [except as eye drops], and LAMAs) 
following screening and were switched to sponsor-provided 
ipratropium bromide (administered four times daily) and 
albuterol sulfate (as needed) to control symptoms during the 
screening period. Patients using a maintenance FDC of an 
inhaled corticosteroid (ICS) and a LABA discontinued this, 
and were switched to the corresponding ICS monotherapy 
(fluticasone, mometasone, or budesonide) at an equivalent 
dose, as well as ipratropium bromide and albuterol sulfate 
(providing they had been maintained on a stable dose of 
the ICS component for $4 weeks prior to screening). Any 
patients taking a maintenance dose of an ICS not adminis-
tered as an FDC with a LABA were allowed to continue using 
the ICS if they had been on a stable dose for $4 weeks prior 
to screening. Ipratropium bromide was discontinued after 
screening. Sponsor-provided albuterol sulfate was permitted, 
as needed, for the relief of symptoms throughout the study.
study population
Patients were 40–80 years of age and had an established clini-
cal history of COPD as defined by the American Thoracic 
Society/European Respiratory Society.12 Inclusion and exclu-
sion criteria were the same as reported for PINNACLE-1 
and PINNACLE-2.5 Briefly, eligible patients were current 
or former smokers ($10 pack-years) with an FEV
1
/forced 
vital capacity ratio of ,0.70 and an FEV
1
 of ,80% predicted 
normal value at screening. Further details are provided in 
the Supplementary materials. Patients were required to 
demonstrate stable baseline FEV
1
, ie, mean predose FEV
1
 
at randomization within ±20% or 200 mL of the mean of 
the predose FEV
1
 assessment obtained at the previous two 
screening visits. The ability of patients to use the MDI cor-
rectly was confirmed at screening, with additional training 
provided as necessary.
assessments
The primary objective of the study was to compare the effi-
cacy of GFF MDI with its monocomponents (GP MDI and 
FF MDI) and placebo MDI and also GP MDI and FF MDI 
with placebo MDI, in patients with moderate-to-very severe 
COPD. Study endpoints differed according to the regional 
regulatory registration requirements. This manuscript reports 
the approach that satisfies the filing requirements of the US 
and China regulatory authorities. Data for similar approaches 
and endpoints satisfying the filing requirements of other 
regions were also generated. The change from baseline in 
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morning predose trough FEV
1
 at Week 24 was the primary 
endpoint. Secondary lung function endpoints included 
change from baseline in morning predose trough FEV
1
 over 
24 weeks, peak change from baseline in FEV
1
 within 2 hours 
postdosing at Week 24, and time to onset of action on Day 1 
(defined as the first time point at which the difference from 
placebo MDI was statistically significant).
Other secondary endpoints included Transition Dyspnea 
Index (TDI) focal score over 24 weeks, change from base-
line in St George’s Respiratory Questionnaire (SGRQ) 
total score at Week 24 (intent-to-treat [ITT] population and 
symptomatic population), and change from baseline in mean 
daily rescue medication use over 24 weeks (rescue medica-
tion user population). Assessments of TDI focal score at 
Week 24 and SGRQ score over Weeks 12–24 were additional 
endpoints. Baseline Dyspnea Index (BDI) and TDI were 
assessed using the interviewer-administrated version of the 
BDI/TDI questionnaire.13,14 Other efficacy endpoints included 
responder analyses to determine the proportion of patients 
achieving an improvement of the minimal clinically important 
difference (MCID) threshold of $1 unit in TDI focal score15 
over 24 weeks and $4 units in SGRQ score16 at Week 24.
Safety assessments included electrocardiograms 
(ECGs), clinical laboratory testing, and vital sign measure-
ments. Adverse events (AEs) were monitored throughout 
the study.
statistical analysis
Unless otherwise specified, results were based on analyses 
using the ITT population (all patients who were randomized 
and received any study treatment, even if ,1 full dose). The 
safety population was the same as the ITT population, except 
patients who were analyzed according to treatment received 
rather than treatment assigned. The symptomatic population 
included all patients in the ITT population with a COPD 
assessment test (CAT) score of $15 at screening. The rescue 
medication user population included all patients in the ITT 
population with the mean baseline rescue medication use 
(albuterol sulfate) of $1 puff/day (calculated from the last 
7 days of the 10–14 days screening period).
A sample size of 1,614 patients was estimated to provide 
91% of power to detect differences for all primary compari-
sons (GFF MDI vs placebo MDI and each monocomponent 
and each monocomponent vs placebo MDI) in the primary 
endpoint (change from baseline in morning predose trough 
FEV
1
 at Week 24) with Type I error controlled at a two-
sided α level of 0.05. The same sample size was estimated 
to provide 99% of power to detect differences for the same 
comparisons for change from baseline in morning predose 
trough FEV
1
 over 24 weeks.
The primary and secondary endpoints (with the excep-
tion of time to onset of action) were analyzed using repeated 
measures linear models (further details in the Supplementary 
materials). Strong control of Type I error (two-sided α=0.05) 
was implemented sequentially across the five key compari-
sons for the primary endpoint and then simultaneously across 
the secondary endpoints within a key comparison using the 
Hochberg procedure (two-sided α=0.05).
Results
Patient disposition
A total of 1,756 patients were randomized and received 
treatment (714 patients from Asia, 496 patients from the 
USA, and 546 patients from Europe [including Russia]), and 
1,528 (87%) patients completed the study (Figure 1). The 
ITT and safety populations included 1,740 patients, of whom 
841 patients were symptomatic (baseline CAT score $15). 
The rescue medication user population comprised 822 
patients. Patient demographics and baseline characteristics 
are summarized in Table 1. The mean age of the patient was 
64.2 years, 74.1% of them were male, and 40.2% of them 
were Asian (56.7% White).
Efficacy
For the primary endpoint of change from baseline in morning 
predose trough FEV
1
 at Week 24, treatment with GFF MDI 
resulted in significantly greater improvements vs placebo 
MDI (least squares mean [LSM] difference: 165 mL; 
P,0.0001; Figure 2 and Table 2), GP MDI (LSM difference: 
59 mL; P,0.0001), and FF MDI (LSM difference: 72 mL; 
P,0.0001). GP MDI and FF MDI treatments significantly 
increased morning predose trough FEV
1
 at Week 24 com-
pared to placebo MDI (LSM difference 105 and 92 mL, 
respectively; both P,0.0001; Figure 2).
Similar improvements as for the primary endpoint were 
observed for change from baseline in morning predose trough 
FEV
1
 over 24 weeks (Figure 2 and Table 2). GFF MDI led 
to significant improvements in peak change from baseline 
in FEV
1
 within 2 hours postdose at Week 24 compared 
to GP MDI, FF MDI, and placebo MDI (Table 2). Onset 
of action for GFF MDI, GP MDI, and FF MDI occurred 
within 5 minutes postdose (LSM differences vs placebo 
MDI 179 mL [P,0.0001], 37 mL [P=0.0002], and 164 mL 
[P,0.0001], respectively).
Significant improvements in TDI focal score over 
24 weeks and SGRQ score at Week 24 were observed in 
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Randomized and received
treatment in PINNACLE-4
(n=1,756)
GFF MDI
18/9.6 µg
(n=555)
GP MDI
18 µg
(n=480)
FF MDI
9.6 µg
(n=483)
Placebo
MDI
(n=238)
61 withdrawals
18 patients discretion
15 adverse events
17 protocol-specified criteria
5 lost to follow-up
3 lack of efficacy
2 major protocol violation
1 investigator discretion
63 withdrawals
23 patients discretion
15 adverse events
14 protocol-specified criteria
3 lost to follow-up
4 lack of efficacy
2 major protocol violation
2 investigator discretion
66 withdrawals
17 patients discretion
14 adverse events
13 protocol-specified criteria
5 lost to follow-up
8 lack of efficacy
5 major protocol violation
4 investigator discretion
38 withdrawals
14 patients discretion
3 adverse events
8 protocol-specified criteria
1 lost to follow-up
8 lack of efficacy
2 major protocol violation
2 investigator discretion
Completed week 24
(n=494) (89.0%)
Completed week 24a
(n=417) (86.9%)
Completed week 24
(n=417) (86.3%)
Completed week 24
(n=200) (84.0%)
Figure 1 Patient disposition.
Note: aOne patient in the gP MDI group completed Week 24 but did not complete the follow-up call (14 days after last study drug dosing), so was categorized as having 
discontinued the study but was not classed as withdrawing from the study.
Abbreviations: FF, formoterol fumarate; gFF, gP/FF; gP, glycopyrrolate; MDI, metered dose inhaler.
both the ITT population and the symptomatic population 
following treatment with GFF MDI compared with GP MDI 
and placebo MDI (P,0.05) but not with FF MDI (Table 3). 
Improvements in TDI score at Week 24 and SGRQ score over 
Weeks 12–24 were also greater following GFF MDI treat-
ment compared to GP MDI and placebo MDI in both popula-
tions (Table S2). Patients treated with GFF MDI were more 
likely to achieve an improvement in at least the MCID for 
TDI score ($1.0 unit) and SGRQ score ($4.0 unit decrease) 
vs placebo MDI and versus GP MDI for TDI score (ITT 
population and symptomatic population; Table 4). Significant 
improvements in rescue medication use were observed for 
GFF MDI vs GP MDI (LSM difference: -0.77; P=0.0001) 
and placebo MDI in the rescue medication user population 
(LSM difference: -0.98; P,0.0001; Table 3).
safety
The incidence of treatment-emergent AEs (TEAEs), 
treatment-related TEAEs, serious TEAEs, or TEAEs lead-
ing to discontinuation was similar across treatment groups 
(Table 5), with the majority of TEAEs being mild or moderate 
and not considered related to study treatment. A relatively 
low proportion of patients (ranging from 4.3% with placebo 
MDI to 5.3% with GP MDI) discontinued due to TEAEs. 
The most commonly reported TEAEs included upper respi-
ratory tract infection, worsening of COPD, headache, and 
hypertension (Table 5).
One death occurred in each of the treatment groups (lung 
cancer [metastatic; n=1 with both GFF MDI and placebo 
MDI], hemorrhagic stroke [GP MDI], and hypoglycemic 
coma [FF MDI]). None of these deaths were judged by the 
investigator to be related to study drug treatment.
Discussion
Treatment with the LAMA/LABA FDC, GFF MDI, 
improved lung function compared to placebo MDI and mono-
components and improved symptoms and patient-reported 
outcomes compared to placebo MDI and GP MDI in a popu-
lation of patients with moderate-to-very severe COPD from 
Asia, Europe, and the USA. Improvements in the primary 
endpoint – change from baseline in morning predose trough 
FEV
1
 at Week 24 – exceeded the MCID of 100 mL17 for 
both GFF MDI and GP MDI vs placebo MDI and were 
significantly higher following treatment with GFF MDI vs 
monocomponents. Overall, results confirmed those from 
previous Phase III studies, which showed GFF MDI to be 
efficacious and well tolerated in a population that included 
patients from the USA, Australia, and New Zealand.5,6
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Improvements in the secondary lung function endpoint 
(peak change from baseline in FEV
1
 within 2 hours postdose 
at Week 24) as well as rescue medication use were signifi-
cantly larger in the GFF MDI treatment arm vs monocom-
ponents and placebo MDI and similar to those observed 
in PINNACLE-1 and PINNACLE-2.5,18 TDI focal scores 
indicated greater reductions in breathlessness following 
GFF MDI treatment than comparators, although treatment 
differences were only significant compared with GP MDI 
and placebo MDI (ITT and symptomatic populations). 
The treatment difference for GFF MDI vs placebo MDI in 
TDI score over 24 weeks was larger than that observed in 
PINNACLE-1 and PINNACLE-2, which may be in part due 
to differences in the method of assessment of TDI score (the 
interviewer-administered version of the TDI was used in this 
study vs the self-administered, computerized version used in 
PINNACLE-1 and PINNACLE-2).19 A larger proportion of 
patients in the GFF MDI group achieved a clinically relevant 
improvement in TDI (total score $1 unit)15 vs GP MDI 
and placebo MDI in the symptomatic and ITT populations, 
demonstrating that GFF MDI was effective in reducing 
breathlessness in patients with COPD. The results of the 
SGRQ assessment in this study suggest that GFF MDI may 
improve health-related quality of life (HRQoL) compared 
Table 1 Patient demographics and baseline characteristics (ITT population)
GFF MDI 
18/9.6 µg 
(n=551)
GP MDI 
18 µg 
(n=474)
FF MDI 
9.6 µg 
(n=480)
Placebo 
MDI 
(n=235)
age (years), mean (sD) 64.7 (7.4) 64.0 (8.1) 64.1 (7.6) 63.9 (7.5)
Male, n (%) 408 (74.0) 346 (73.0) 365 (76.0) 171 (72.8)
race, n (%)
White
Black/african american
asian
american Indian or alaska native
315 (57.2)
12 (2.2)
223 (40.5)
1 (0.2)
275 (58.0)
18 (3.8)
181 (38.2)
0
260 (54.2)
16 (3.3)
204 (42.5)
0
137 (58.3)
6 (2.6)
92 (39.1)
0
BMI (kg/m2), mean (sD) 26.3 (5.9) 26.5 (5.7) 26.3 (6.2) 26.2 (6.2)
smoking status, n (%)
Current
Former
number of pack-years smoked,a mean (sD)
252 (45.7)
299 (54.3)
45.9 (24.3)
209 (44.1)
265 (55.9)
44.8 (25.5)
208 (43.3)
272 (56.7)
46.9 (26.1)
113 (48.1)
122 (51.9)
45.7 (26.4)
COPD severity,b n (%)
Mildc
Moderate
severe
Very severe
6 (1.1)
330 (59.9)
192 (34.8)
23 (4.2)
9 (1.9)
283 (59.7)
168 (35.4)
14 (3.0)
5 (1.0)
290 (60.4)
171 (35.6)
14 (2.9)
6 (2.6)
137 (58.3)
86 (36.6)
6 (2.6)
COPD duration (years), mean (sD) (n=546)
6.2 (5.9)
(n=474)
6.2 (5.8)
(n=477)
6.1 (6.2)
(n=234)
6.1 (5.6)
Postbronchodilator FeV1 (% predicted), mean (sD) (n=550)
53.96 (13.73)
(n=472)
54.82 (14.08)
(n=480)
53.92 (13.22)
(n=235)
54.40 (13.90)
reversibility to albuterol
reversible,d n (%)
reversibility postbronchodilator for FeV1 (%), mean (sD)
249 (45.2)
17.5 (15.2)
207 (43.7)
16.9 (13.8)
207 (43.1)
17.3 (14.6)
108 (46.0)
18.1 (15.9)
Use of ICs,e n (%) 169 (30.7) 143 (30.2) 142 (29.6) 79 (33.6)
BDI focal score, mean (sD) (n=532)
6.7 (2.2)
(n=457)
6.7 (2.3)
(n=458)
6.8 (2.2)
(n=217)
6.2 (2.2)
sgrQ total score, mean (sD) (n=489)
40.8 (16.9)
(n=412)
39.4 (17.7)
(n=415)
38.7 (16.9)
(n=196)
41.7 (17.2)
CaT total score,f mean (sD) (n=550)
14.9 (7.0)
(n=472)
15.2 (7.3)
(n=480)
14.9 (7.0)
(n=235)
15.2 (7.4)
rescue medication useg (puffs/day), mean (sD) (n=256)
4.3 (3.4)
(n=225)
4.0 (2.7)
(n=232)
4.1 (2.8)
(n=109)
4.1 (2.9)
Notes: anumber of pack-years smoked = (number of cigarettes each day/20) × number of years smoked. bseverity of COPD was based on the nonmissing postalbuterol 
assessment at screening. cThese patients were characterized as having mild COPD due to the application of an asian correction factor to baseline lung function assessments 
at the time of analysis. dReversible is defined as improvement in FEV1 postalbuterol administration compared to the prealbuterol of $12% or $200 ml. 
eDefined as using 
ICS on the day of the first dose of study medication. fCaT total score is the sum of eight CaT item scores (range: 0–40). grescue medication use was analyzed in the rescue 
medication user population, defined as all patients in the ITT population with the mean baseline rescue albuterol sulfate use of $1 puff/day.
Abbreviations: BDI, Baseline Dyspnea Index; BMI, body mass index; CaT, COPD assessment test; FF, formoterol fumarate; gFF, glycopyrrolate/formoterol fumarate; gP, 
glycopyrrolate; ICs, inhaled corticosteroid; ITT, intent-to-treat; MDI, metered dose inhaler; sgrQ, st george’s respiratory Questionnaire.
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Figure 2 lsM change (±se) from baseline in morning predose trough FeV1 over 24 weeks (ITT population).
Abbreviations: FF, formoterol fumarate; gFF, gP/FF; gP, glycopyrrolate; ITT, intent-to-treat; lsM, least squares mean; MDI, metered dose inhaler; se, standard error.
Table 2 Primary and secondary lung function endpoints (ITT population)
GFF MDI 18/9.6 µg GP MDI 18 µg FF MDI 9.6 µg Placebo MDI
Primary endpoint
Change from baseline in morning predose trough FeV1 at Week 24 (ml)
n
lsM
se
488
120
9.1
412
60
9.9
413
47
9.9
196
-45
14.3
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
59 (33, 86)
,0.0001a
72 (46, 99)
,0.0001a
165 (132, 198)
,0.0001a
Secondary endpoints
Change from baseline in morning predose trough FeV1 over 24 weeks
b (ml)
n
lsM
se
541
135
7.0
465
80
7.6
467
63
7.6
225
-20
10.9
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
55 (35, 76)
,0.0001a
72 (52, 92)
,0.0001a
155 (129, 180)
,0.0001a
Peak change from baseline in FeV1 within 2 hours postdosing at Week 24 (ml)
n
lsM
se
490
358
10.2
412
214
11.1
413
247
11.1
196
55
16.0
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
145 (115, 174)
,0.0001a
111 (81, 140)
,0.0001a
303 (266, 340)
,0.0001a
Notes: aStatistically significant/superior. bMorning predose trough FeV1 over 24 weeks was based on assessments at Weeks 2, 4, 8, 12, 16, 20, and 24.
Abbreviations: FF, formoterol fumarate; gFF, glycopyrrolate/formoterol fumarate; gP, glycopyrrolate; ITT, intent-to-treat; lsM, least squares mean; MDI, metered dose 
inhaler; na, not applicable; se, standard error.
with placebo MDI and GP MDI, which is consistent with 
the results of PINNACLE-1.5,18 Although the improvements 
seen with GFF MDI in patient-reported outcomes (TDI 
and SGRQ) were not statistically significant vs FF MDI, 
both treatments were effective in improving symptoms vs 
placebo. Differences between active treatments for patient-
reported outcomes can be small and, therefore, these outcome 
measures may not be sensitive in indicating differences 
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between active treatments. Ultimately, the superior effects 
of GFF MDI vs FF MDI on lung function may result in 
greater benefits for patients’ quality of life when sustained 
over a longer time period than the 24-week duration of the 
current study. In the long-term PINNACLE-3 safety study, 
treatment with GFF MDI resulted in statistically significant 
improvements in TDI score and numerical improvements in 
SGRQ, over 52 weeks compared with FF MDI.6
Although no head-to-head comparisons between 
GFF MDI and other LAMA/LABA FDCs have been reported, 
the magnitude of improvements in lung function, rescue 
medication use, and HRQoL vs monocomponents observed 
in this study followed a similar trend to those of pivotal 
studies with other LAMA/LABA FDCs.20–27 While several 
other efficacious and well-tolerated LAMA/LABA FDC 
combinations are available for the maintenance treatment of 
COPD, GFF MDI is notably the first to be delivered using an 
MDI. The co-suspension delivery technology used to formu-
late GFF MDI overcame formulation challenges encountered 
with MDIs,28 resulting in consistent in vitro aerosol perfor-
mance, even in the presence of simulated patient-handling 
errors,29 providing reliable drug dose delivery to all regions 
of the lungs with high efficiency.30 As familiarity with an 
inhaler can result in more favorable clinical outcomes in 
respiratory disease31,32 and MDIs remain a commonly pre-
scribed device type for rescue medication,33 the availability 
Table 3 secondary patient-reported outcome endpoints (ITT population, unless stated otherwise)
GFF MDI 18/9.6 µg GP MDI 18 µg FF MDI 9.6 µg Placebo MDI
TDI focal score over 24 weeksa
n
lsM
se
532
1.6
0.09
457
1.3
0.10
458
1.5
0.10
217
0.8
0.14
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
0.33 (0.07, 0.59)
0.0125b
0.15 (-0.11, 0.41)
0.2530
0.80 (0.47, 1.13)
,0.0001b
TDI focal score over 24 weeksa (symptomatic population)c
n
lsM
se
244
1.5
0.14
228
1.1
0.15
217
1.3
0.15
108
0.7
0.22
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
0.41 (0.01, 0.81)
0.0425b,c
0.20 (-0.21, 0.60)
0.3379
0.73 (0.22, 1.23)
0.0048b,c
Change from baseline in sgrQ total score at Week 24
n
lsM
se
489
-5.3
0.54
412
-3.7
0.59
415
-5.6
0.59
196
-0.9
0.86
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
-1.62 (-3.19, -0.05)
0.0427b
0.30 (-1.27, 1.87)
0.7084
-4.40 (-6.39, -2.41)
,0.0001b
Change from baseline in sgrQ total score at Week 24 (symptomatic population)c
n
lsM
se
220
-6.9
0.88
202
-3.8
0.91
189
-7.8
0.95
92
-1.6
1.37
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
-3.10 (-5.59, -0.61)
0.0148b
0.89 (-1.65, 3.44)
0.4908
-5.33 (-8.52, -2.14)
0.0011b
Change from baseline in mean daily rescue medication use over 24 weeksd (puffs/day) (rescue medication user population)
n
lsM
se
256
-1.4
0.13
225
-0.6
0.14
232
-1.0
0.14
109
-0.4
0.21
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
-0.77 (-1.16, -0.38)
0.0001b
-0.41 (-0.80, -0.03)
0.0345e
-0.98 (-1.47, -0.49)
,0.0001b
Notes: aTDI focal score over 24 weeks was based on assessments at Weeks 4, 8, 12, 16, 20, and 24. bStatistically significant/superior. cThe symptomatic population was 
defined as patients in the ITT population with a COPD assessment test score $15 at baseline (screening). dThe rescue medication user population was defined as all patients 
in the ITT population with the mean baseline rescue albuterol sulfate use of $1 puff/day. eNominally significant (ie, P,0.05 but not statistically significant due to procedure 
to control Type I error).
Abbreviations: FF, formoterol fumarate; gFF, glycopyrrolate/formoterol fumarate; gP, glycopyrrolate; ITT, intent-to-treat; lsM, least squares mean; MDI, metered dose 
inhaler; na, not applicable; se, standard error; sgrQ, st george’s respiratory Questionnaire; TDI, Transition Dyspnea Index.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
4.
36
.1
39
.4
5 
on
 1
7-
O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2976
lipworth et al
Table 4 responder analyses for MCID of secondary, patient-reported outcome endpoints (ITT population)
GFF MDI 18/9.6 µg GP MDI 18 µg FF MDI 9.6 µg Placebo MDI
Proportion of patients achieving the MCID thresholda
$1 unit improvement in TDI focal score over 24 weeks
n
responders, n (%)
548
313 (57.11)
474
223 (47.14)
477
256 (53.73)
235
88 (37.19)
Treatment comparison for gFF MDI vs monocomponents and placebo MDI
Or (95% CI)
P-value
na
na
1.49 (1.17, 1.91)
0.0015b
1.15 (0.90, 1.47)
0.2785
2.25 (1.64, 3.08)
,0.0001b
$1 unit improvement in TDI focal score over 24 weeks (symptomatic population)c
n
responders, n (%)
255
137 (53.80)
239
92 (38.49)
228
115 (50.38)
117
43 (36.70)
Treatment comparison for gFF MDI vs monocomponents and placebo MDI
Or (95% CI)
P-value
na
na
1.86 (1.30, 2.66)
0.0007b
1.15 (0.80, 1.64)
0.4540
2.01 (1.28, 3.15)
0.0024b
$4 unit improvement from baseline in sgrQ total score at Week 24
n
responders, n (%)
549
256 (46.31)
474
193 (40.51)
480
219 (46.19)
235
81 (33.06)
Treatment comparison for gFF MDI vs monocomponents and placebo MDI
Or (95% CI)
P-value
na
na
1.27 (0.98, 1.63)
0.0669
1.00 (0.78, 1.29)
0.9696
1.75 (1.27, 2.41)
0.0007b
$4 unit improvement from baseline in sgrQ total score at Week 24 (symptomatic population)c
n
responders, n (%)
255
125 (48.78)
239
100 (41.78)
229
112 (49.50)
117
35 (28.80)
Treatment comparison for gFF MDI vs monocomponents and placebo MDI
Or (95% CI)
P-value
na
na
1.33 (0.93, 1.90)
0.1229
0.97 (0.68, 1.39)
0.8757
2.35 (1.47, 3.77)
0.0004b
Notes: Percentages are based on a logistic regression model with TDI or sgrQ response as a binary response (response/no response). relevant baseline value (BDI or 
sgrQ) and reversibility to albuterol sulfate were continuous covariates, and treatment was a categorical covariate. aValidated thresholds for the MCID for each endpoint 
were used.34 bStatistically significant/superior. cThe symptomatic population was defined as patients in the ITT population with a COPD assessment test score of $15 at 
baseline (screening).
Abbreviations: BDI, Baseline Dyspnea Index; FF, formoterol fumarate; gFF, glycopyrrolate/formoterol fumarate; gP, glycopyrrolate; ITT, intent-to-treat; MCID, minimum 
clinically important difference; MDI, metered dose inhaler; sgrQ, st george’s respiratory Questionnaire; TDI, Transition Dyspnea Index.
Table 5 summary of aes (safety population)
GFF MDI 18/9.6 µg 
(n=551)
GP MDI 18 µg 
(n=474)
FF MDI 9.6 µg 
(n=480)
Placebo MDI 
(n=235)
Teaes, n (%)
Patients with $1 Teae 306 (55.5) 250 (52.7) 256 (53.3) 131 (55.7)
Patients with Teaes relateda to study treatment 55 (10.0) 51 (10.8) 46 (9.6) 23 (9.8)
Patients with serious Teaes 53 (9.6) 34 (7.2) 40 (8.3) 19 (8.1)
Patients with serious Teaes relateda to study treatment 3 (0.5) 4 (0.8) 4 (0.8) 2 (0.9)
Patients with Teaes leading to early discontinuation 27 (4.9) 25 (5.3) 24 (5.0) 10 (4.3)
Deaths (all cause) during treatment period 1 (0.2) 1 (0.2) 1 (0.2) 1 (0.4)
Deaths (all cause) during treatment period +14 days 1 (0.2) 1 (0.2) 1 (0.2) 1 (0.4)
aes occurring in $2% of patients in any treatment arm (preferred term), n (%)
Viral upper respiratory tract infection 50 (9.1) 44 (9.3) 46 (9.6) 16 (6.8)
Upper respiratory tract infection 37 (6.7) 33 (7.0) 29 (6.0) 20 (8.5)
COPDb 16 (2.9) 12 (2.5) 13 (2.7) 7 (3.0)
headache 15 (2.7) 11 (2.3) 10 (2.1) 3 (1.3)
hypertension 16 (2.9) 6 (1.3) 3 (0.6) 8 (3.4)
Cough 13 (2.4) 10 (2.1) 8 (1.7) 2 (0.9)
Dyspnea 11 (2.0) 6 (1.3) 7 (1.5) 7 (3.0)
Back pain 15 (2.7) 7 (1.5) 5 (1.0) 1 (0.4)
Dizziness 8 (1.5) 12 (2.5) 4 (0.8) 1 (0.4)
Pneumonia 9 (1.6) 5 (1.1) 5 (1.0) 6 (2.6)
Bronchitis 4 (0.7) 8 (1.7) 6 (1.3) 5 (2.1)
Pharyngitis 11 (2.0) 3 (0.6) 4 (0.8) 0
Notes: arelated = possibly, probably, or definitely related in the opinion of the investigator. bWorsening of COPD defined as a COPD exacerbation since the patient’s last 
visit. COPD exacerbations were only recorded as an ae if they were considered to be a serious Teae.
Abbreviations: ae, adverse event; FF, formoterol fumarate; gFF, glycopyrrolate/formoterol fumarate; gP, glycopyrrolate; MDI, metered dose inhaler; Teae, treatment-
emergent ae.
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of a LAMA/LABA FDC delivered by MDI offers a useful 
option for the maintenance treatment of COPD. A Phase III 
study has shown that the addition of a spacer does not affect 
the lung function benefits and tolerability of GFF MDI,35 sug-
gesting that this FDC could be a treatment option for patients 
who require a spacer to compensate for poor hand-to-breath 
coordination with an MDI.
A potential limitation of this study was the short dura-
tion (6 months) relative to expected use as prophylactic 
therapy. However, the long-term safety and efficacy of 
GFF MDI have been evaluated over a 1-year period during 
the PINNACLE-3 safety extension study.6 Additionally, 
patients could have potentially perceived benefit from par-
ticipation in a study of the novel co-suspension delivery 
technology MDI. However, placebo was delivered by the 
same device as the active treatments to control for effects 
due to patient perception. The strength of this study was that 
patients were enrolled from sites across Asia, Europe, and 
the USA, allowing the efficacy and safety of GFF MDI to 
be evaluated in patients from a broad range of geographical 
locations and socioeconomic backgrounds. Patients were 
not required to be symptomatic at baseline for enrollment, 
though results were analyzed in a subgroup of patients 
with a CAT score of $15 (48% of patients randomized), 
which provided an insight into the efficacy of GFF MDI in 
symptomatic patients.
Conclusion
The results of PINNACLE-4 demonstrate that GFF MDI 
improves lung function, symptoms, and patient-reported 
outcomes in a study population including patients from Asia, 
Europe, and the USA. These results are consistent with pre-
vious Phase III studies with GFF MDI, which showed that 
this LAMA/LABA FDC was efficacious and well tolerated 
with no unexpected safety signals in patients with moderate-
to-very severe COPD.
Abbreviations
AE, adverse event; BDI, Baseline Dyspnea Index; BMI, 
body mass index; CAT, COPD assessment test; ECG, elec-
trocardiogram; FDC, fixed-dose combination; FF, formoterol 
fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, 
glycopyrrolate; HRQoL, health-related quality of life; ICS, 
inhaled corticosteroid; ITT, intent-to-treat; LABA, long-
acting β
2
-agonist; LAMA, long-acting muscarinic antago-
nist; LSM, least squares mean; MCID, minimum clinically 
important difference; MDI, metered dose inhaler; SE, stan-
dard error; SGRQ, St George’s Respiratory Questionnaire; 
TDI, Transition Dyspnea Index; TEAE, treatment-emergent 
adverse event.
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Supplementary materials
study design and inclusion/exclusion 
criteria
A randomization ratio of 7:6:6:3 was used, as initial model-
ing suggesting that this is the most efficient for the sample 
size and treatments in this study. The appropriateness of 
this ratio was confirmed by the results of PINNACLE-1 and 
PINNACLE-2.1
Patients were 40–80 years of age, had an established clini-
cal history of COPD as defined by the American Thoracic Soci-
ety/European Respiratory Society,2 and were current or former 
smokers with a history of at least 10 pack-years. COPD had 
to be of at least moderate severity,3 defined as a FEV
1
/forced 
vital capacity ratio of ,0.70 at screening, and FEV
1
 ,80% 
predicted normal value (calculated using the Third National 
Health and Nutrition Examination Survey4 or local refer-
ence equations applicable to other regions) and $750 mL if 
FEV
1
 ,30% predicted normal (ie, very severe COPD).
Exclusion criteria included diagnosis of a significant 
disease other than COPD (which, in the opinion of the inves-
tigator, could put the patient at risk or could influence either 
the study results or the patient’s ability to participate); poorly 
controlled COPD (defined as acute worsening of COPD that 
required treatment with oral corticosteroids or antibiotics 
within 6 weeks of, or during, screening); and hospitalization 
due to poorly controlled COPD within 3 months prior to, or 
during, screening. The need for long-term oxygen therapy 
(.12 hour/day), change in smoking status within 6 weeks 
of or during screening, and poor hand-to-breath coordination 
(requiring the use of a spacer device with an MDI) were also 
exclusion criteria.
statistical analysis
The primary endpoint was analyzed using a repeated mea-
sures linear model with baseline FEV
1
 (the mean of evaluable 
60- and 30-minute predose values on Day 1) and reversibil-
ity to albuterol sulfate as continuous covariates and visit, 
treatment, and treatment-by-visit interaction as categorical 
covariates. An unstructured variance–covariance matrix 
was applied, and two-sided P-values and point estimates 
with two-sided 95% CIs were produced for each treatment 
difference. Treatment group comparisons for the secondary 
endpoints were evaluated using a similar repeated measures 
linear model as for the primary endpoint but included the rel-
evant baseline covariate for each endpoint. Time to onset of 
action on Day 1 was determined for each treatment using the 
5 and 15-minute postdosing FEV
1
 assessments and analyzed 
using an analysis of covariance model, with baseline FEV
1
 
and reversibility to albuterol sulfate as continuous covariates. 
For Transition Dyspnea Index and St George’s Respiratory 
Questionnaire responder analyses, logistic regression was 
used to compare treatment groups and P-values and odds 
ratios with 95% CIs were produced for each comparison. 
The procedure to control Type I error was applied to primary 
and secondary endpoints only and is described in the main 
body of the article.
Table S1 Institutional review boards and approval numbers 
Institutional review board Approval numbera
schulman associate Institutional review Board, Inc., 4445 lake Forrest Drive, suite 300, 
Cincinnati, Oh 45242, Usa
201500174
Fakultni nemocnice Kralovske Vinohrady, The University hospital Kralovske Vinohrady, 
srobarova 50, 100 34 Praha 10, Czech republic
reference number MeK/08/0/2015
ethik-Kommission bei der landesarztekammer hessen, Im Vogelsgesang 3, 60488 Frankfurt, 
germany
registration number FF 23/2015
nres Committee london-Bloomsbury, hra nres Centre Manchester, Barlow house 3rd 
Floor, 4 Minshull street, Manchester M1 3DZ, UK
reC reference 15/lO/0523
Iras project 167822
egyeszegugyi Tudomanyos Tanacs, Klinikai Farmakologiai etikai Bizottsaga, arany Janos u 6-8, 
1051 Budapest, hungary
reference number OgYI/32844-2/2015
Korea University anam hospital, 73, Inchon-ro, seongbuk-gu, seoul 136-705, Korea IrB number eD14345
review number an14345-001
Institutional review Board of Yeungnam University hospital, 170, hyeonchung-ro, nam-gu, 
Deagu 705-703, Korea
IRB file number YUMC 2015-02-008
Institutional review Board of The Catholic University of Korea st Paul’s hospital, 180, 
Wangsan-ro, Dongdaemun-gu, seoul 130-709, Korea
Document number PIrB-00131-003
study number PC15MggT0002
Institutional review Board of Kyunghee University hospital, 23, Kyungheedae-ro, 
Dongdaemun-gu, seoul 130-872, Korea
IRB file number KHUH 2015-02-102-005
Institutional review Board of Korea University guro hospital, 148, gurodong-ro, guro-gu, 
seoul 152-703, Korea
approval number KUgh14324-001
(Continued)
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Table S1 (Continued)
Institutional review board Approval numbera
Dong-a University hospital Institutional review Board, 26 Daesingongwon-ro, seo-gu, Busan 
602-715, Korea 
study number15-022
Institution review Board of Yonsei University Wonju severance Christian hospital, 20, IIsan-
ro, Wonju-si, gangwon-Do 220-701, Korea
approval number Cr115030
Institution review Board of Inje University seoul Paik hospital, 31, supyo-ro, Jung-gu, seoul 
100-032, Korea
study number sIT-2015-003
Komisja Bioetyczna, Okregowej Izby lekarskiej w Bialymstoku, Ul swietojanska 7, 15-082 
Bialystok, Poland
5/2015/VI
Independent Interdisciplinary Committee on ethics evaluation of Clinical Trials (Central IrB), 
51, leningradsky Prospect, Moscow 125468, russia
489298-20-1
ethics Committee at Federal state governmental establishment “Burdenko Main Military 
Clinical hospital” of russian Federation Défense Ministry, 3, hospital sq, Moscow 105229, 
russia
489298-20-1
local ethics Committee of saint Petersburg state Budgetary healthcare Institution, 
“Consulting and Diagnostic Center # 85”, pr Veteranov, 89, bld 3, saint Petersberg 198260, 
russia
489298-20-1
local ethics Committee of state Budgetary healthcare Institutions of leningrad region (sBhI 
lr), “gatchina Clinical Interdistrict hospital”, roshchinskaya  str. 15a, gatchina, leningard 
region, russia
489298-20-1
local ethics Committee Of sBhI lr “Occupational Pathology Center”, 27, liter O, 
Mechnikova pr, saint Petersburg 195271, russia
Protocol number 22/2015 
local ethics Committee of sBeI hPe “Pavlov First saint Petersburg state Medical University”, 
of the Ministry of healthcare of the russian Federation, 10, rentgena str, saint Petersburg 
197101, russia
489298-20-1
Independent Ethics Committee of Federal State Budgetary Institution “Central Scientific and 
research Institute of Tuberculosis” of russian academy of Medical science, 2, Yauzskaya 
alleya, Moscow 107564, russia
489298-20-1
local ethics Committee, The Ministry of healthcare of the russian Federation state Budgetary 
educational Institution of higher Professional education, IM sechenov First Moscow state 
Medical University, 8-2 Trubetskaya str, Moscow 119991, russia
na
local ethics Committee of state Budgetary education Institution of higher Professional 
education, Pavlov First saint Petersburg state Medical University, 10, rentgena str, saint 
Petersburg 197101, russia
489298-20-1
local ethics Committee Of state Budgetary healthcare Institution of stavropol region (sBhI sr), 
City hospital #2 of Pyatigorsk, 6, admiralskogo str, 357538 Pyatigorsk, stavropol region, russia
493403-20-1
Chang gung Medical Foundation Institutional review Board, no 5, Fusing st, gueishan 
Township, Taoyuan City, Taiwan, rOC
na
China Medical University & hospital research ethics Committee, no 2, Yude rd, north Dist, 
Taichung City 40447, Taiwan, rOC
na
The Institutional review Board of Taichung Veterans general hospital, 1650 Taiwan 
Boulevard sect 4, Taichung 40705, Taiwan, rOC
IrB TCVgh number sC15104a
research ethic Committee C of national Taiwan University hospital Members, no 1, 
Changde street, Taipei City 100, Taiwan, rOC
nTUh-rec number 201504046MsC
Ino hospital Institutional review Board, 1-27 shiosaki Oshio-cho, himeji-shi, hyogo 671-
0102, Japan
na
nihon University hospital’s Joint Institutional review Board, 30-1 Oyaguchi kamicho, 
Itabashi-ku, Tokyo 173-8610, Japan
File number 2706-1430
nagata hospital Institutional review Board, 523-1 shimomiyanagagamachi, Yanagawa-shi, 
Fukuoka 832-0059, Japan
na
Institutional review Board of national hospital Organization Tenryu hospital, 4201-2 Oro, 
hamakita-ku, hamamatsu-shi, shizuoka 434-8511, Japan
na
Dokkyo Medical University hospital Institutional review Board, 880 Kitakobayashi, 
Mibu-machi, shimotsuga-gun, Tochigi 321-0293, Japan
File number s-288
Institutional review Board of Kishiwada City hospital, 1001 gakuhara-cho, Kishiwada-shi, 
Osaka 596-8501, Japan
na
Takamatsu Municipal hospital Institutional review Board, 2-36-1 Miyawakicho, Takamatsu, 
Kagawa 760-8538, Japan
na
(Continued)
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Table S1 (Continued)
Institutional review board Approval numbera
national hospital Organization Fukuoka hospital Institutional review Board, 4-39-1 
Yakatabaru, Minami-ku, Fukuoka-shi, Fukuoka 811-1394, Japan
File number 2015C1
review Board of human rights and ethics for Clinical studies Institutional review Board, 13-2 
Ichiban-cho, Chiyoda-ku, Tokyo 102-0082, Japan
na
Tohoku rosai hospital Institutional review Board, 4-3-2-1, Dainohara, aoba-ku, sendai-city, 
Miyagi 981-8563, Japan
File number 15a003a
Institutional review Board of Ishikawa Prefectural Central hospital, 2-1 Kuratsukihgashi, 
Kanazawa, Ishikawa 920-8530, Japan
na
Institution review Board of national hospital Organization, Ibarakihigashi national hospital, 
825 Terunuma, Tokai-mura, naka-gun, Ibaraki 319-1113, Japan
na
review Board of human rights and ethics for Clinical studies Institutional review Board, 13-2 
Ichiban-cho, Chiyoda-ku, Tokyo 102-0082, Japan
na
Institutional review Board of nagaoka red Cross hospital, 2-297-1 sensyu, nagaoka-shi, 
niigata 940-2085, Japan
na
national hospital Organization Fukuoka higashi Medical Center Institutional review Board, 
1-1-1 Chidori, Koga-shi, Fukuoka 811-3195, Japan
na
The IrB of Tosei general hospital, 160 nishioiwake-cho, seto, aichi 489-8642, Japan File number h270501PT
Kobe City Medical Center general hospital Institutional review Board, 2-1-1 Minatojima-
minamimachi, Chuo-ku, Kobe-shi, hyogo 650-0047, Japan
File number Chi 15-08
The IrB of healthcare corporation Tesshokai, 1344, higashi-cho, Kamogawa City, 
Chiba 296-0041, Japan
na
Institutional review Board of shinshu University hospital, 3-1-1 asahi, Matsumoto, nagano 
390-8621, Japan
File number 1482
sendai Open hospital Institutional review Board, 5-22-1 Tsurugaya Miyagino-ku, sendai, 
Miyagi 983-0824
na
The Institution review Board of Japan Community healthcare Organization Chukyo hospital, 
1-1-10 sanjo, Minami-ku, nagoya-shi, aichi 457-8510, Japan
File number 15-003
The Institution review Board of national hospital Organization ehime Medical Center, 366 
Yokogawara, Toon-shi, ehime 791-0281, Japan
File number 2015-B-03
The Institution review Board of Marianna University school of Medicine, 2-16-1, sugao, 
Miyamae-ku, Kawasaki-shi, Kanagawa 216-8511, Japan
File number a219 
The Institution review Board of national hospital Organization asahikawa Medical Center, 
7-4048, hanasaki-cho, asahikawa-shi, hokkaido 070-0901, Japan
File number 15-a-7
adachi Kyosai hospital Institutional review Board, 1-36-8 Yanagihara, adachi-ku, 
Tokyo 120-0022, Japan
na
Institutional review Board of shintokai Yokohama Minoru Clinic, 1-13-8, Bessho, Minami-ku, 
Yokohama-shi, Kanagawa 232-0064, Japan
na
Japan Conference of Clinical research Institutional review Board, 2F, Ichigo Minami Ikebukuro 
Building, 2-27-17, Mianami Ikebururo, Toshima-ku, Tokyo 171-0022, Japan
File number 3-175
Tokyo-eki Center-building Clinic Institutional review Board, 3-3-14, nihonbashi, Churo-ku, 
Tokyo 103-0027, Japan
File number 3-173
nanfang hospital southern Medical University, no 1838, north of guangzhou avenue, 
guangzhou, guangdong Province 510515, China
approval number nFeC-2016-006
ethics Committee of The second Xiangya hospital of Central south University, no 139, 
Middle renmin road, Changsha, hunan Province 410011, China
CFDa approval 2015l03321
Medical Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University, 
151, Yan Jiang Xi road, guangzhou (Canton) 510120, China
eC review (2015) number 26
CFDa approval 2015l03321
Medical ethics Committee of guangdong general hospital, no 106, Zhongshan second road, 
guangzhou, guangdong Province 510080, China
CFDa approval 20l5l03321
ethics Committee of hebei general hospital, no 348, hepingxi road, shijazhuang, hebei, 
China
study number Y-2015-22
CFDa approval 2015l03321
ethics Committee of First hospital of shanxi Medical University, no 85, JieFang road, Taiyuan, 
shanxi Province 030001, China
(2016) eC review number 01
sFDa approval 2015l03321
Ethics Committee of the First Affiliated Hospital of Soochow University, No 188 Shinzi Street, 
suzhou, Jiangsu Province 215006, China
eC number 2015100
sFDa approval 2015l03321
ethics Committee of hainan general hospital, F3, Information Building, no 19, Xiuhua road, 
Xiuying District, haikou, hainan 570311, China
CFDa approval number 2015l03321
(Continued)
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Table S1 (Continued)
Institutional review board Approval numbera
ethics Committee of Wuxi people’s hospital, no 299, Qingyang road, Wuxi Jiangsu Province 
214023, China
approval number 2015llPJ-III-18
Ethics Committee of the Second Affiliated Hospital of Nanchang University, No 1, Minde 
road, Donghu District, nanchang, Jiangxi 330006, China
CFDa approval number 2015l03321
IEC for Clinical Research of Zhongda Hospital, Affiliated to Southeast University, No 87, 
Dingjaqiao road, gulou District, nanjing, Jiangsu Province 210009, China
approval number 2015ZDsYll083.0
Clinical Trial ethics Committee of West China hospital, sichuan University, no 37, guoxue 
lane, Wuhou District, Chengdu, sichuan 610041, China
CFDa approval number 2015l03321
Medical ethic Committee of The general hospital of shenyang Military Command, no 83, 
Wenhua road, shenhe District, shenyang, liaoning 110016, China
CFDa approval number 2015l03321
The Clinical research ethics Committee of anhui Provincial hospital, no 17, lunjiang road, 
hefei City, anhui Province, China
sFDa approval number 2015l03321 
approval number 2016 eC number 03 
The first Hospital of Jilin University Ethics Committee, No 71 Xinmin Main Street, Changchun, 
Jilin Province, China
CFDa approval number 2015l03321
Trial review number 160225-013
ethics Committee of the People’s hospital of guangxi Zhuang autonomous region, no 6, 
Taoyuan road, nanning, guangxi 530021, China
CFDa approval number 2015l03321
Inner Mongolia People’s hospital clinical trial ethics Committee, no 20, Zhaowuda rd, 
hohhot, Inner Mongolia 010017, China
Clinical trial protocol identify number 
YWlCsYll2015-11
CFDa approval number 2015l03321
ethics Committee of Beijing Friendship hospital, Capital Medical hospital, no 95, Yongan 
road, Xicheng District, Beijing, China
CFDa approval number 2015l03321
ethics Committee of Peking University shou gang hospital, no 9, Jinyuanzhuang road, 
shijingshan District, Beijing, China
eC review approval IrB-aF-27-04
The drug clinical trial ethics Committee of Chengdu Military general hospital, no 2, gonghe 
road, Chengdong district, Xining, China
Project number CDa2015Y032
Issue number 20150015
ethics Committee of shanghai Pulmonary hospital, no 507, Zhengmin road, shanghai 200433, 
China
approval number 15136hX
CFDa approval number 2015l03321
ethics Committee of the second hospital of hebei Medical University, no 215, hepingxi 
road, shijazhuang, hebei, China
study number 2016eC02-05-1
CFDa approval number 2015l03321
ethics Committee of Beijing anzhen hospital, Capital Medical University, no 2, anzhen road, 
Chaoyang District, Beijing, China
accepted number 2015-63D
approval number 2016 number 2
CFDa approval number 2015l03321
ethics Committee of guizhou Provincial People’s hospital, no 83, east Zhongshan rd, 
guiyang, guizhou 55002, China
sFDa approval number 2015l03321
Medical ethic Committee of shengjing hospital of China Medical University, no 36, sanhao 
street, heping District, shenyang, liaoning 110004, China
eC review number 2015Ps32
CFDa approval number 2015l03321
Ethics Committee of Huadong Hospital Affiliated to Fudan University, No 221, West Yan’an 
road, Jing’an District, shanghai 200040, China
approval number 20150238
Protocol number in the ethics 
Committee document 2015l041
ethics Committee of Zhongshan hospital Xiamen University, no 201-209, south hubin road, 
Xiamen, Fujian 361004, China
approval number 2016 eC number 11
accepted number 20160001
CFDa approval number 2015l03321
Qinghai Provincial People’s hospital Clinical Trial ethics Committee, no 2, gonghe road, 
Chengdong District, Xining, China
approval number PJ2016-001-001
Drug ethics Committee of Tianjin Medical University general hospital, no 154 an shan ave, 
heping District, Tianjin 300052, China
approval number IrB2016-018-01 ZYY-
IrB-sOP-016 (F)-002-03 
ethics Committee of shanghai east hospital, no 150, Jimo road, Pudong District, shanghai 
200120, China
approval number (2016) number 007 
Clinical review
ethics Committee of Yiyang Central hospital, no 118, Kangfu north road, Yiyang, hunan, 
China
CFDa approval number 2015l03321
Note: aApproval numbers are shown where available (some IRBs provided reference or file numbers and some did not assign approval numbers).
Abbreviations: IrBs, institutional review boards; na, not available; reC, research ethic Committee; Iras, Integrated research approval system; TCVgh, Taichung 
Veterans general hospital; nTUh-rec, national Taiwan University hospital research ethic Committee; CFDa, China Food and Drug administration; eC, ethics committee; 
sFDa, state Food and Drug administration.
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Table S2 additional patient-reported outcome endpoints (ITT population, unless stated otherwise)
GFF MDI 18/9.6 µg GP MDI 18 µg FF MDI 9.6 µg Placebo MDI
TDI focal score at Week 24
n
lsM
se
487
1.8
0.12
410
1.4
0.13
413
1.6
0.13
196
0.9
0.19
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
0.41 (0.06, 0.75)
0.0229
0.20 (-0.15, 0.55)
0.2659
0.90 (0.46, 1.34)
,0.0001
TDI focal score at Week 24 (symptomatic population)a
n
lsM
se
219
1.7
0.19
201
1.1
0.20
188
1.6
0.20
91
0.8
0.29
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
0.63 (0.10, 1.17)
0.0202
0.11 (-0.43, 0.66)
0.6879
0.87 (0.19, 1.55)
0.0122
Change from baseline in sgrQ total score over 12–24 weeksb
n
lsM
se
516
-5.2
0.46
436
-3.6
0.50
436
-5.0
0.50
205
-1.7
0.72
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
-1.62 (-2.94, -0.30)
0.0165
-0.27 (-1.59, 1.05)
0.6908
-3.50 (-5.18, -1.82)
,0.0001
Change from baseline in sgrQ total score over 12–24 weeksb (symptomatic population)a
n
lsM
se
237
-6.9
0.76
218
-3.9
0.79
200
-7.3
0.83
97
-3.1
1.19
Treatment difference for gFF MDI vs monocomponents and placebo MDI
lsM (95% CI)
P-value
na
na
-2.99 (-5.15, -0.84)
0.0066
0.32 (-1.89, 2.53)
0.7787
-3.83 (-6.60, -1.06)
0.0068
Notes: aThe symptomatic population was defined as patients in the ITT population with a COPD assessment test score $15 at baseline (screening). bsgrQ score over 
12–24 weeks was based on assessments at Weeks 12, 16, 20, and 24.
Abbreviations: FF, formoterol fumarate; gFF, glycopyrrolate/formoterol fumarate; gP, glycopyrrolate; ITT, intent to treat; lsM, least squares mean; MDI, metered dose 
inhaler; na, not applicable; se, standard error; sgrQ, st george’s respiratory Questionnaire; TDI, Transition Dyspnea Index.
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